Kits Eyecare: 90x Earnings on 20% Growth Is a Rich Bridge With Nowhere to Go

The competitor asking whether Kits Eyecare's profit growth justifies a roughly 90x P/E is asking the wrong question. The right question is simpler: is any P/E above roughly 30 defensible for a consumer e-commerce operator with 5% EBITDA margins and thin absolute earnings? The answer today is no. The stock's operating metrics are improving, but the valuation has outrun the proof, and the catalyst path for another leg of multiple expansion is faint.

Kits Eyecare (TSX: KITS) reported second-quarter 2026 results today, and they were solid by the company's own trajectory. Revenue of C$58.4 million, up 17.8% year-over-year, and the company also reported its 15th consecutive quarter of positive adjusted EBITDA. Glasses revenue - the growth engine management has been building - accelerated 54% to C$11.1 million, now nearly 19% of total revenue versus 14.5% a year ago. Repeat revenue, which anchors the recurring contact lens business, grew 27.4% to C$38.3 million, or 65.5% of the top line. Average order value hit a record C$213, up 15.8% year-over-year.

The company also generated record operating cash flow of C$7.8 million for the quarter, which converts to C$6.4 million of free cash flow after capital expenditures. That figure looks impressive until you note that operating cash flow at 13.3% of revenue is roughly 2.7 times adjusted EBITDA. Working capital swings, not profit, are the primary driver. Still, the business ends the quarter with C$27.4 million in cash, zero debt, and a C$15 million undrawn credit facility. The balance sheet is clean.

But clean balance sheets don't justify 90x trailing earnings.

Here is the arithmetic the headline P/E obscures. Over the last twelve months, Kits Eyecare generated C$5.63 million in net income on C$222.2 million of revenue. That is a 2.5% net profit margin. The company's gross margin sits at 37.2%, operating margin at 3.8%, and EBITDA margin at 5.5%. These are respectable for a growth-stage direct-to-consumer operator reinvesting heavily in customer acquisition - marketing was 17.4% of revenue in Q2, up from 15.2% a year ago - but they are not the margins of a company that commands a premium multiple.

The market is implicitly pricing Kits as if those margins are on a deterministic path to 15% or higher. That assumption requires several things to happen in concert: glasses revenue must continue growing at 50%+ rates while its mix premiumizes, marketing spend must decline as a percentage of revenue even as the company acquires roughly 90,000 new customers per quarter, and fulfillment costs must compress further. Management says the business is "paying for its own acceleration." That's true - but the acceleration is still modest in absolute dollar terms.

The valuation bridge matters here. At a C$490.6 million market cap, the trailing P/E sits near 90x. Sources vary slightly on the exact figure - between 90x and 97x depending on whether you use TTM net income or a smoothed earnings run rate - but the range is the point. The forward P/E is closer to 50x, based on consensus estimates that push full-year 2026 net income toward the C$9–C$10 million range. Even at 50x forward earnings, the stock demands flawless execution for the rest of 2026 and into 2027.

To put that in context, the EV/EBITDA multiple is 38.5x. That is a multiple you see for high-growth software platforms with 40%+ gross margins, 80%+ net retention, and recurring revenue that compounds without proportionate sales expense. Kits has none of those SaaS characteristics. It is a physical-goods retailer shipping prescription lenses and frames, competing on price, convenience, and digital fit technology. The product category is non-discretionary enough to provide visibility, but the unit economics don't approach software-like leverage.

The growth numbers are the strongest part of the story, and they deserve credit. Glasses revenue has compounded from a handful of million-dollar quarters to a category now approaching C$22 million in the first half of 2026. Premium lens upgrades - higher-margin add-ons - represent 45.2% of glasses revenue, and management says the premiumization trend is accelerating. The auto-ship program for contact lenses has built a C$24.6 million annuity. The two-year active customer base reached 1.1 million, up 15.2% year-over-year. These are the kinds of retention and mix metrics that suggest durable demand.

But growth at this valuation needs a near-term catalyst to justify holding through volatility, and the Q3 guidance is not that catalyst. Management guided third-quarter revenue to C$62–C$64 million with adjusted EBITDA margin between 4% and 6%. Those numbers represent continued growth but nothing that changes the earnings trajectory materially. The Q3 midpoint revenue of C$63 million is roughly 7.5% sequential growth over Q2's C$58.4 million, which is good but not transformative. And adjusted EBITDA margin guidance of 4–6% keeps the profitability question alive rather than answering it.

The stock has also been under pressure for over a year. The 52-week price change is down roughly 14%, and the share price is trading below its 200-day moving average of C$15.39. Some of that decline reflects broader small-cap growth stock weakness - rising rate concerns, CAD volatility, and sector rotation out of tech-enabled retail. But a significant portion reflects the arithmetic problem this article is flagging: the market bid for Kits has been inconsistent with the scale of actual earnings, and that tension hasn't resolved.

The bull case is straightforward. If glasses growth stays above 50%, repeat revenue penetration continues toward 70%, marketing spend compresses toward 15% of revenue, and EBITDA margins push toward 8–10% in the second half of 2026, then net income could approach C$12–C$14 million on an annualized basis. At that point, a 35–40x forward multiple - still generous but defensible for a growth compounder - would support a stock price well above current levels. That path requires strong second-half execution but is not unreasonable given the trend line.

The bear case is equally straightforward. Consumer spending is showing moderation in Canada. Marketing spend is rising, not falling, suggesting customer acquisition is getting more expensive, not cheaper. Glasses - while growing fast - remains a small enough portion of revenue that a slowdown in that category would hit the blended growth rate hard. And at current valuation, even a quarter of flat EBITDA margins or decelerating revenue growth would invite another multiple contraction.

The verdict sits between those cases. The operating trends are real and worth respecting. The balance sheet is pristine. The business is generating cash. But the valuation is demanding a level of operating acceleration that the company has not yet proven it can sustain at this scale.

Kits Eyecare is a Hold. The growth story is intact, but at roughly 90x trailing earnings, the stock has priced in years of flawless execution. Investors would be better served waiting for either a valuation reset toward a forward multiple in the 30–40x range, or for two consecutive quarters of 8%+ adjusted EBITDA margins that would justify the current price with less reliance on future assumptions. The Q3 results, expected in early November, will be the first real test of whether margin expansion is accelerating or stalling.